AMENDMENTS IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended): A compound of formula (I)



(I)

wherein

R is $(C_1\text{-}C_8)$-alkyl, $(C_0\text{-}C_8)$-alkylene-aryl, $(C_3\text{-}C_8)$-cycloalkyl, $(C_1\text{-}C_4)$-alkoxy-$(C_1\text{-}C_4)$-alkyl, $(C_2\text{-}C_8)$-alkenyl, $(C_2\text{-}C_8)$-alkynyl, a 3- to 12-membered mono-, bi- or spirocyclic ring optionally containing one ~~or more~~ heteroatom~~s~~ selected from the group consisting of N, O, and S, and wherein the 3- to 12-membered ring is optionally substituted by F, Cl, Br, NO_2, CF_3, OCF_3, CN, $(C_1\text{-}C_6)$-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-$(C_1\text{-}C_6)$-alkyl, S-$(C_1\text{-}C_6)$-alkyl, <u>or</u> N(R15)CO$(C_1\text{-}C_6)$-alkyl ~~or COO-$(C_1\text{-}C_6)$-alkyl~~;

R11, R12, R13, R14 and R15 independently are H or $(C_1\text{-}C_6)$-alkyl;

B is a bond or a linker ~~comprising~~ <u>of</u> one or two radicals selected from the group consisting of $(C(R19)(R20))_i$, C(OR21)(R22), O, N(R23), S, SO, SO_2, and CO;

i is 1, 2 or 3;

R19, R20, R21, R22 and R23 independently are H, $(C_1\text{-}C_6)$-alkyl or aryl;

R1, R2, R3, and R4 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_1\text{-}C_4)$-alkoxy-$(C_1\text{-}C_4)$-alkyl, S-$(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, $(C_3\text{-}C_8)$-cycloalkyl, O-$(C_3\text{-}C_8)$-cycloalkyl, $(C_3\text{-}C_8)$-cycloalkenyl, O-$(C_3\text{-}C_8)$-cycloalkenyl, $(C_2\text{-}C_6)$-alkynyl, $(C_0\text{-}C_8)$-alkylene-aryl, O-$(C_0\text{-}C_8)$-alkylene-aryl, S-aryl, N(R24)(R25), SO_2-CH_3, ~~COOH, COO-$(C_1\text{-}C_6)$-alkyl,~~ CON(R26)(R27), N(R28)CO(R29), N(R30) SO_2(R31) or CO(R32);

R24, R25, R26, R27, R28 and R30 independently are H or $(C_1$-$C_6)$-alkyl;

R29, R31,and R32 independently are H, $(C_1$-$C_6)$-alkyl or aryl;

W is $-(CH_2)_n$-, -CH=CH-, -CH=N- or –N=CH-;

n is 2, 3, 4 or 5;

R5, R6, R7 and R8 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, S-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_3$-$C_8)$-cycloalkyl, O-$(C_3$-$C_8)$-cycloalkyl, $(C_3$-$C_8)$-cycloalkenyl, O-$(C_3$-$C_8)$-cycloalkenyl, $(C_2$-$C_6)$-alkynyl, $(C_0$-$C_8)$-alkylene-aryl, O-$(C_0$-$C_8)$-alkylene-aryl, S-aryl, N(R33)(R34), SO_2-CH_3, ~~COOH, COO-$(C_1$-$C_6)$-alkyl,~~ CON(R35)(R36), N(R37)CO(R38), N(R39) SO_2(R40), CO(R41) or a 5- to 7-membered heterocycle having 1 ~~to 4~~ heteroatoms selected from the group consisting of O, N and S;

R33 and R34 independently are H or $(C_1$-$C_6)$-alkyl, or
R33 and R34 form together with the nitrogen atom to which they are bonded a 5- or 6-membered ring wherein when R33 and R34 form together with the nitrogen to which they are bonded a 6-membered ring, one CH_2 group of the 6-membered ring optionally is O or S;

R35, R36, R37 and R39 independently are H or $(C_1$-$C_6)$-alkyl;

R38, R40 and R41 independently are H, $(C_1$-$C_6)$-alkyl or aryl;

A is a chain $-(C(R42)(R43))_m$- wherein 0 to 2 members of the chain are optionally replaced by an element selected from the group consisting of O, S, N(R44), CO and SO_2;

m is 0, 1, 2, 3, 4 or 5;

R42, R43, R44 independently are H, $(C_1$-$C_6)$-alkyl or aryl;

R9 and R10 independently are H, (C_1-C_8)-alkyl, $-(CH_2)_o$-R45, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, aryloxy-(C_1-C_4)-alkyl, (C_3-C_8)-alkenyl, (C_3-C_8)-alkynyl, CO-(C_1-C_8)-alkyl, CO-$(CH_2)_o$R45, CO-(C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, CO-aryloxy-(C_1-C_4)-alkyl, CO-(C_2-C_8)-alkenyl, CO-(C_2-C_8)-alkynyl, or

R9 and R10 form together with the nitrogen atom to which they are bonded a 4- to 10-membered mono-, bi- or spirocyclic ring wherein said ring, apart from the nitrogen atom, may optionally contain 0 to 4 additional heteroatoms selected from the group consisting of O, N and S and wherein said ring optionally is substituted by F, Cl, Br, CF_3, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_8)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, (C_0-C_8)-alkylene-aryl, oxo, CO(R46), CON(R47)(R48), OH, ~~COO(R49),~~ N(R50)CO(C_1-C_6)-alkyl, N(R51)(R52) or SO_2CH_3;

R46, R47, R48, ~~R49,~~ R50, R51 and R52 independently are H or (C_1-C_4)-alkyl;

o is 0, 1, 2, 3, 4, 5 or 6;

R45 is OH, CH(aryl)$_2$, a 3- to 12-membered mono- or bicyclic ring which optionally contains one or more heteroatoms selected from the group consisting of N, O and S wherein the 3- to 12-membered ring optionally is substituted by F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, oxo, O-(C_1-C_6)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, S-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_3-C_8)-cycloalkyl, O-(C_3-C_8)-cycloalkyl, (C_3-C_8)-cycloalkenyl, O-(C_3-C_8)-cycloalkenyl, (C_2-C_6)-alkynyl, (C_0-C_8)-alkylene-aryl, O-(C_0-C_8)-alkylene-aryl, S-aryl, N(R51)(R52), SO_2-CH_3 or COOH; or

a pharmaceutically acceptable salt of the compound of formula I.

2. (currently amended): The compound according to claim 1 wherein

R is (C_1-C_6)-alkyl, (C_0-C_2)-alkylene-aryl, (C_3-C_8)-cycloalkyl, (C_2-C_6)-alkenyl, (C_5-C_8)-cycloalkenyl, (C_7-C_8)-bicycloalkenyl, (C_2-C_6)-alkynyl or a 3- to 7-membered ring optionally containing one ~~or more~~ heteroatom~~s~~ selected form the group consisting of N, O, and S, and wherein the 3- to 7-membered ring is optionally substituted by F, Cl, Br, NO_2,

CF_3, OCF_3, CN, $(C_1\text{-}C_6)$-alkyl, CON(R11)(R12), N(R13)(R14), OH, O-$(C_1\text{-}C_6)$-alkyl or N(R15)CO$(C_1\text{-}C_6)$-alkyl ~~or COO-$(C_1\text{-}C_6)$-alkyl~~;

B is a bond O, S, SO_2, CO, OCH(R20), N(R23), CH_2 or CH_2CH_2;

R20 and R23 independently are H or $(C_1\text{-}C_6)$-alkyl;

R1, R2, R3, and R4 independently are H, F, Cl, Br, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_1\text{-}C_4)$-alkoxy-$(C_1\text{-}C_4)$-alkyl, S-$(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_2)$-alkylene-aryl, O-$(C_0\text{-}C_2)$-alkylene-aryl, N(R24)(R25), SO_2-CH_3, ~~COOH, COO-$(C_1\text{-}C_6)$-alkyl,~~ CON(R26)(R27), N(R28)CO(R29) or CO(R32);

R29 and R32 independently are H, $(C_1\text{-}C_6)$-alkyl or aryl;

n is 2, 3 or 4;

R5, R6, R7 and R8 independently are H, F, Cl, Br, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_2)$-alkylene-aryl, O-$(C_0\text{-}C_2)$-alkylene-aryl, ~~COO-$(C_1\text{-}C_6)$-alkyl~~ or CO(R41);

R41 is $(C_1\text{-}C_6)$-alkyl or aryl;

A is a chain $-(C(R42)(R43))_m$- wherein 1 to 2 members of the chain are optionally replaced by an element selected from the group consisting of O, N(R44) and CO;

m is 3 or 4;

R9 and R10 independently are H, $(C_1\text{-}C_8)$-alkyl, -$(CH_2)_o$-R45, $(C_1\text{-}C_4)$-alkoxy-$(C_1\text{-}C_4)$-alkyl, aryloxy-$(C_1\text{-}C_4)$-alkyl, $(C_3\text{-}C_8)$-alkenyl, $(C_3\text{-}C_8)$-alkynyl, CO-$(C_1\text{-}C_8)$-alkyl or CO-$(CH_2)_o$R45; or

R9 and R10 form together with the nitrogen atom to which they are bonded a 4- to 10-membered mono-, bi- or spirocyclic ring wherein said ring, apart from the nitrogen atom, may optionally contain 0 to 2 additional heteroatoms selected from the group consisting of O, N and S and wherein said ring optionally is substituted by F, Cl, Br, CF_3, CN, $(C_1\text{-}C_6)$-

alkyl, O-(C_1-C_8)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, (C_0-C_2)-alkylene-aryl, oxo, CO(R46), CON(R47)(R48), OH, ~~COO(R49),~~ N(R50)CO(C_1-C_6)-alkyl, N(R51)(R52) or SO_2CH_3;

o is 0, 1, 2, 3 or 4;

R45 is OH, a 3- to 12-membered mono- or bicyclic ring which optionally contains one or two heteroatoms selected from the group consisting of N, O and S wherein the 3- to 12-membered ring optionally is substituted by F, Cl, Br, OH, CF_3, NO_2, CN, OCF_3, oxo, O-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_0-C_2)-alkylene-aryl, O-(C_0-C_2)-alkylene-aryl, N(R51)(R52), SO_2-CH_3 or COOH.

3. (currently amended): The compound according to claim 2 wherein

R is (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl, or a 5- to 6-membered mono- or bicyclic ring optionally containing one ~~or two~~ heteroatoms selected from the group consisting of N, O, and S, wherein the 5- to 6-membered ring is optionally substituted by F, Cl, Br, NO_2, CF_3, OCF_3, CN, (C_1-C_6)-alkyl or O-(C_1-C_6)-alkyl;

B is a bond, O, S, $COOCH_2$, N(R23) or CH_2;

R23 is H or (C_1-C_6)-alkyl;

R1, R2, R3, and R4 independently are H, F, Cl, Br, CF_3, O-(C_1-C_6)-alkyl or (C_1-C_6)-alkyl;

W is –CH=CH- or –N=CH-;

R5, R6, R7 and R8 independently are H, F, Cl, Br, OH, CF_3, NO_2, CN, OCF_3 or O-(C_1-C_6)-alkyl;

A is a chain –(C(R42)(R43))$_m$- wherein 1 member of the chain is optionally replaced by an element selected from the group consisting of O and N(R44);

R9 and R10 independently are H, $(C_1\text{-}C_8)$-alkyl, $\text{-}(CH_2)_o\text{-}R45$ or $CO\text{-}(C_1\text{-}C_8)$-alkyl;

or

R9 and R10 form together with the nitrogen atom to which they are bonded a 4- to 10-membered mono-, bi- or spirocyclic ring wherein said ring, apart from the nitrogen atom, may optionally contain 0 to 2 additional heteroatoms selected from the group consisting of O, N and S, and wherein said ring optionally is substituted by F, $(C_1\text{-}C_6)$-alkyl, $O\text{-}(C_1\text{-}C_8)$-alkyl, oxo, CO(R46), CON(R47)(R48), OH, $N(R50)CO(C_1\text{-}C_6)$-alkyl or N(R51)(R52);

R45 is OH, a 5- to 10-membered mono- or bicyclic ring which optionally contains one or two heteroatoms selected from the group consisting of N, O and S, wherein the 5- to 10-membered ring optionally is substituted by F, Cl, Br, OH, CF_3, oxo, $O\text{-}(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_2)$-alkylene-aryl, $O\text{-}(C_0\text{-}C_2)$-alkylene-aryl or N(R51)(R52).

4. (original): The compound according to claim 3 wherein W is –CH=CH-.

5. (original): The compound according to claim 3 wherein m is 3 and R42, R43 and R44 are H.

6. (original): The compound according to claim 3 wherein R5, R6, R7 and R8 are H.

7. (original): The compound according to claim 3 wherein A and B are each disposed in the para position relative to the central W-containing heterocycle.

8. (original): The compound according to claim 7 which is 1-[4-(2-dimethylaminoethoxy)-phenyl]-3-(4-phenoxyphenyl)-1,3-dihydroimidazol-2-one.

9. (withdrawn): A method for the treatment or prevention of excessive weight or obesity in mammals comprising administering to said mammal a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of formula (I)



(I)

wherein

R is (C_1-C_8)-alkyl, (C_0-C_8)-alkylene-aryl, (C_3-C_8)-cycloalkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, (C_2-C_8)-alkenyl, (C_2-C_8)-alkynyl, a 3- to 12-membered mono-, bi- or spirocyclic ring optionally containing one or more heteroatoms selected from the group consisting of N, O, and S, and wherein the 3- to 12-membered ring is optionally substituted by F, Cl, Br, NO_2, CF_3, OCF_3, CN, (C_1-C_6)-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-(C_1-C_6)-alkyl, S-(C_1-C_6)-alkyl, N(R15)CO(C_1-C_6)-alkyl or COO-(C_1-C_6)-alkyl;

R11, R12, R13, R14 and R15 independently are H or (C_1-C_6)-alkyl;

B is a bond or a linker comprising one or two radicals selected from the group consisting of $(C(R19)(R20))_i$, C(OR21)(R22), O, N(R23), S, SO, SO_2, and CO;

i is 1, 2 or 3;

R19, R20, R21, R22 and R23 independently are H, (C_1-C_6)-alkyl or aryl;

R1, R2, R3, and R4 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)-alkyl, O-(C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, S-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_3-C_8)-cycloalkyl, O-(C_3-C_8)-cycloalkyl, (C_3-C_8)-cycloalkenyl, O-(C_3-C_8)-cycloalkenyl, (C_2-C_6)-alkynyl, (C_0-C_8)-alkylene-aryl, O-(C_0-C_8)-alkylene-aryl, S-aryl, N(R24)(R25), SO_2-CH_3, COOH, COO-(C_1-C_6)-alkyl, CON(R26)(R27), N(R28)CO(R29), N(R30) SO_2(R31) or CO(R32);

R24, R25, R26, R27, R28 and R30 independently are H or (C_1-C_6)-alkyl;

R29, R31,and R32 independently are H, (C_1-C_6)-alkyl or aryl;

W is $-(CH_2)_n$-, -CH=CH-, -CH=N- or –N=CH-;

n is 2, 3, 4 or 5;

R5, R6, R7 and R8 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)-alkyl, O-(C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, S-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-

alkenyl, (C_3-C_8)-cycloalkyl, O-(C_3-C_8)-cycloalkyl, (C_3-C_8)-cycloalkenyl, O-(C_3-C_8)-cycloalkenyl, (C_2-C_6)-alkynyl, (C_0-C_8)-alkylene-aryl, O-(C_0-C_8)-alkylene-aryl, S-aryl, N(R33)(R34), SO_2-CH_3, COOH, COO-(C_1-C_6)-alkyl, CON(R35)(R36), N(R37)CO(R38), N(R39) SO_2(R40), CO(R41) or a 5- to 7-membered heterocycle having 1 to 4 heteroatoms selected from the group consisting of O, N and S;

R33 and R34 independently are H or (C_1-C_6)-alkyl, or
R33 and R34 form together with the nitrogen atom to which they are bonded a 5- or 6-membered ring wherein when R33 and R34 form together with the nitrogen to which they are bonded a 6-membered ring, one CH_2 group of the 6-membered ring optionally is O or S;

R35, R36, R37 and R39 independently are H or (C_1-C_6)-alkyl;

R38, R40 and R41 independently are H, (C_1-C_6)-alkyl or aryl;

A is a chain $-(C(R42)(R43))_m-$ wherein 0 to 2 members of the chain are optionally replaced by an element selected from the group consisting of O, S, N(R44), CO and SO_2;

m is 0, 1, 2, 3, 4 or 5;

R42, R43, R44 independently are H, (C_1-C_6)-alkyl or aryl;

R9 and R10 independently are H, (C_1-C_8)-alkyl, $-(CH_2)_o$-R45, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, aryloxy-(C_1-C_4)-alkyl, (C_3-C_8)-alkenyl, (C_3-C_8)-alkynyl, CO-(C_1-C_8)-alkyl, CO-$(CH_2)_o$R45, CO-(C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, CO-aryloxy-(C_1-C_4)-alkyl, CO-(C_2-C_8)-alkenyl, CO-(C_2-C_8)-alkynyl, or
R9 and R10 form together with the nitrogen atom to which they are bonded a 4- to 10-membered mono-, bi- or spirocyclic ring wherein said ring, apart from the nitrogen atom, may optionally contain 0 to 4 additional heteroatoms selected from the group consisting of O, N and S and wherein said ring optionally is substituted by F, Cl, Br, CF_3, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_8)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, (C_0-C_8)-alkylene-aryl, oxo,

CO(R46), CON(R47)(R48), OH, COO(R49), N(R50)CO(C_1-C_6)-alkyl, N(R51)(R52) or SO_2CH_3;

R46, R47, R48, R49, R50, R51 and R52 independently are H or (C_1-C_4)-alkyl;

o is 0, 1, 2, 3, 4, 5 or 6;

R45 is OH, CH(aryl)$_2$, a 3- to 12-membered mono- or bicyclic ring which optionally contains one or more heteroatoms selected from the group consisting of N, O and S wherein the 3- to 12-membered ring optionally is substituted by F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, oxo, O-(C_1-C_6)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, S-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_3-C_8)-cycloalkyl, O-(C_3-C_8)-cycloalkyl, (C_3-C_8)-cycloalkenyl, O-(C_3-C_8)-cycloalkenyl, (C_2-C_6)-alkynyl, (C_0-C_8)-alkylene-aryl, O-(C_0-C_8)-alkylene-aryl, S-aryl, N(R51)(R52), SO_2-CH_3 or COOH.

10. (withdrawn): A method of treating a disease or psychiatric indication in mammals which comprises administering to said mammal a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of formula (I)



(I)

wherein

R is (C_1-C_8)-alkyl, (C_0-C_8)-alkylene-aryl, (C_3-C_8)-cycloalkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, (C_2-C_8)-alkenyl, (C_2-C_8)-alkynyl, a 3- to 12-membered mono-, bi- or spirocyclic ring optionally containing one or more heteroatoms selected from the group consisting of N, O, and S, and wherein the 3- to 12-membered ring is optionally substituted by F, Cl, Br, NO_2, CF_3, OCF_3, CN, (C_1-C_6)-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-(C_1-C_6)-alkyl, S-(C_1-C_6)-alkyl, N(R15)CO(C_1-C_6)-alkyl or COO-(C_1-C_6)-alkyl;

R11, R12, R13, R14 and R15 independently are H or (C_1-C_6)-alkyl;

B is a bond or a linker comprising one or two radicals selected from the group consisting of $(C(R19)(R20))_i$, C(OR21)(R22), O, N(R23), S, SO, SO_2, and CO;

i is 1, 2 or 3;

R19, R20, R21, R22 and R23 independently are H, $(C_1\text{-}C_6)$-alkyl or aryl;

R1, R2, R3, and R4 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_1\text{-}C_4)$-alkoxy-$(C_1\text{-}C_4)$-alkyl, S-$(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, $(C_3\text{-}C_8)$-cycloalkyl, O-$(C_3\text{-}C_8)$-cycloalkyl, $(C_3\text{-}C_8)$-cycloalkenyl, O-$(C_3\text{-}C_8)$-cycloalkenyl, $(C_2\text{-}C_6)$-alkynyl, $(C_0\text{-}C_8)$-alkylene-aryl, O-$(C_0\text{-}C_8)$-alkylene-aryl, S-aryl, N(R24)(R25), $SO_2\text{-}CH_3$, COOH, COO-$(C_1\text{-}C_6)$-alkyl, CON(R26)(R27), N(R28)CO(R29), N(R30) SO_2(R31) or CO(R32);

R24, R25, R26, R27, R28 and R30 independently are H or $(C_1\text{-}C_6)$-alkyl;

R29, R31,and R32 independently are H, $(C_1\text{-}C_6)$-alkyl or aryl;

W is $-(CH_2)_n$-, -CH=CH-, -CH=N- or –N=CH-;

n is 2, 3, 4 or 5;

R5, R6, R7 and R8 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_1\text{-}C_4)$-alkoxy-$(C_1\text{-}C_4)$-alkyl, S-$(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, $(C_3\text{-}C_8)$-cycloalkyl, O-$(C_3\text{-}C_8)$-cycloalkyl, $(C_3\text{-}C_8)$-cycloalkenyl, O-$(C_3\text{-}C_8)$-cycloalkenyl, $(C_2\text{-}C_6)$-alkynyl, $(C_0\text{-}C_8)$-alkylene-aryl, O-$(C_0\text{-}C_8)$-alkylene-aryl, S-aryl, N(R33)(R34), $SO_2\text{-}CH_3$, COOH, COO-$(C_1\text{-}C_6)$-alkyl, CON(R35)(R36), N(R37)CO(R38), N(R39) SO_2(R40), CO(R41) or a 5- to 7-membered heterocycle having 1 to 4 heteroatoms selected from the group consisting of O, N and S;

R33 and R34 independently are H or $(C_1\text{-}C_6)$-alkyl, or
R33 and R34 form together with the nitrogen atom to which they are bonded a 5- or 6-membered ring wherein when R33 and R34 form together with the nitrogen to which they

are bonded a 6-membered ring, one CH_2 group of the 6-membered ring optionally is O or S;

R35, R36, R37 and R39 independently are H or $(C_1$-$C_6)$-alkyl;

R38, R40 and R41 independently are H, $(C_1$-$C_6)$-alkyl or aryl;

A is a chain $-(C(R42)(R43))_m$- wherein 0 to 2 members of the chain are optionally replaced by an element selected from the group consisting of O, S, N(R44), CO and SO_2;

m is 0, 1, 2, 3, 4 or 5;

R42, R43, R44 independently are H, $(C_1$-$C_6)$-alkyl or aryl;

R9 and R10 independently are H, $(C_1$-$C_8)$-alkyl, $-(CH_2)_o$-R45, $(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, aryloxy-$(C_1$-$C_4)$-alkyl, $(C_3$-$C_8)$-alkenyl, $(C_3$-$C_8)$-alkynyl, CO-$(C_1$-$C_8)$-alkyl, CO-$(CH_2)_o$R45, CO-$(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, CO-aryloxy-$(C_1$-$C_4)$-alkyl, CO-$(C_2$-$C_8)$-alkenyl, CO-$(C_2$-$C_8)$-alkynyl, or
R9 and R10 form together with the nitrogen atom to which they are bonded a 4- to 10-membered mono-, bi- or spirocyclic ring wherein said ring, apart from the nitrogen atom, may optionally contain 0 to 4 additional heteroatoms selected from the group consisting of O, N and S and wherein said ring optionally is substituted by F, Cl, Br, CF_3, NO_2, CN, $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_8)$-alkyl, $(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, $(C_0$-$C_8)$-alkylene-aryl, oxo, CO(R46), CON(R47)(R48), OH, COO(R49), N(R50)CO$(C_1$-$C_6)$-alkyl, N(R51)(R52) or SO_2CH_3;

R46, R47, R48, R49, R50, R51 and R52 independently are H or $(C_1$-$C_4)$-alkyl;

o is 0, 1, 2, 3, 4, 5 or 6;

R45 is OH, $CH(aryl)_2$, a 3- to 12-membered mono- or bicyclic ring which optionally contains one or more heteroatoms selected from the group consisting of N, O and S wherein the 3- to 12-membered ring optionally is substituted by F, Cl, Br, I, OH, CF_3, NO_2,

CN, OCF_3, oxo, O-(C_1-C_6)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, S-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_3-C_8)-cycloalkyl, O-(C_3-C_8)-cycloalkyl, (C_3-C_8)-cycloalkenyl, O-(C_3-C_8)-cycloalkenyl, (C_2-C_6)-alkynyl, (C_0-C_8)-alkylene-aryl, O-(C_0-C_8)-alkylene-aryl, S-aryl, N(R51)(R52), SO_2-CH_3 or COOH.

11. (withdrawn): The method of claim 10 wherein the disease or psychiatric indication is selected from the group consisting of Type II diabetes, arteriosclerosis, high blood pressure, depression, anxiety, anxiety neuroses and schizophrenia.

12. (withdrawn): The method of claim 11 wherein the disease is Type II diabetes.

13. (withdrawn): The method of claim 11 wherein the disease is arteriosclerosis.

14. (withdrawn): The method of claim 11 wherein the disease is high blood pressure.

15. (withdrawn): The method of claim 11 wherein the psychiatric indication is depression.

16. (withdrawn): The method of claim 11 wherein the psychiatric indication is anxiety or anxiety neuroses.

17. (withdrawn): The method of claim 11 wherein the psychiatric indication is schizophrenia.

18. (withdrawn): A method for the treatment or prevention of excessive weight or obesity in mammals comprising administering to said mammal a therapeutically effective amount of a mixture of one or more antiobesity agents or appetite-regulating active ingredients and a compound, or a pharmaceutically acceptable salt thereof, of formula (I)



(I)

wherein

R is (C_1-C_8)-alkyl, (C_0-C_8)-alkylene-aryl, (C_3-C_8)-cycloalkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, (C_2-C_8)-alkenyl, (C_2-C_8)-alkynyl, a 3- to 12-membered mono-, bi- or spirocyclic ring optionally containing one or more heteroatoms selected from the group consisting of N,

O, and S, and wherein the 3- to 12-membered ring is optionally substituted by F, Cl, Br, NO_2, CF_3, OCF_3, CN, $(C_1$-$C_6)$-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-$(C_1$-$C_6)$-alkyl, S-$(C_1$-$C_6)$-alkyl, N(R15)CO$(C_1$-$C_6)$-alkyl or COO-$(C_1$-$C_6)$-alkyl;

R11, R12, R13, R14 and R15 independently are H or $(C_1$-$C_6)$-alkyl;

B is a bond or a linker comprising one or two radicals selected from the group consisting of $(C(R19)(R20))_i$, C(OR21)(R22), O, N(R23), S, SO, SO_2, and CO;

i is 1, 2 or 3;

R19, R20, R21, R22 and R23 independently are H, $(C_1$-$C_6)$-alkyl or aryl;

R1, R2, R3, and R4 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, S-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_3$-$C_8)$-cycloalkyl, O-$(C_3$-$C_8)$-cycloalkyl, $(C_3$-$C_8)$-cycloalkenyl, O-$(C_3$-$C_8)$-cycloalkenyl, $(C_2$-$C_6)$-alkynyl, $(C_0$-$C_8)$-alkylene-aryl, O-$(C_0$-$C_8)$-alkylene-aryl, S-aryl, N(R24)(R25), SO_2-CH_3, COOH, COO-$(C_1$-$C_6)$-alkyl, CON(R26)(R27), N(R28)CO(R29), N(R30) SO_2(R31) or CO(R32);

R24, R25, R26, R27, R28 and R30 independently are H or $(C_1$-$C_6)$-alkyl;

R29, R31,and R32 independently are H, $(C_1$-$C_6)$-alkyl or aryl;

W is $-(CH_2)_n$-, -CH=CH-, -CH=N- or –N=CH-;

n is 2, 3, 4 or 5;

R5, R6, R7 and R8 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, S-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_3$-$C_8)$-cycloalkyl, O-$(C_3$-$C_8)$-cycloalkyl, $(C_3$-$C_8)$-cycloalkenyl, O-$(C_3$-$C_8)$-cycloalkenyl, $(C_2$-$C_6)$-alkynyl, $(C_0$-$C_8)$-alkylene-aryl, O-$(C_0$-$C_8)$-alkylene-aryl, S-aryl, N(R33)(R34), SO_2-CH_3, COOH, COO-$(C_1$-$C_6)$-alkyl, CON(R35)(R36), N(R37)CO(R38),

N(R39) SO_2(R40), CO(R41) or a 5- to 7-membered heterocycle having 1 to 4 heteroatoms selected from the group consisting of O, N and S;

R33 and R34 independently are H or (C_1-C_6)-alkyl, or
R33 and R34 form together with the nitrogen atom to which they are bonded a 5- or 6-membered ring wherein when R33 and R34 form together with the nitrogen to which they are bonded a 6-membered ring, one CH_2 group of the 6-membered ring optionally is O or S;

R35, R36, R37 and R39 independently are H or (C_1-C_6)-alkyl;

R38, R40 and R41 independently are H, (C_1-C_6)-alkyl or aryl;

A is a chain –(C(R42)(R43))$_m$- wherein 0 to 2 members of the chain are optionally replaced by an element selected from the group consisting of O, S, N(R44), CO and SO_2;

m is 0, 1, 2, 3, 4 or 5;

R42, R43, R44 independently are H, (C_1-C_6)-alkyl or aryl;

R9 and R10 independently are H, (C_1-C_8)-alkyl, -(CH_2)$_o$-R45, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, aryloxy-(C_1-C_4)-alkyl, (C_3-C_8)-alkenyl, (C_3-C_8)-alkynyl, CO-(C_1-C_8)-alkyl, CO-(CH_2)$_o$R45, CO-(C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, CO-aryloxy-(C_1-C_4)-alkyl, CO-(C_2-C_8)-alkenyl, CO-(C_2-C_8)-alkynyl, or
R9 and R10 form together with the nitrogen atom to which they are bonded a 4- to 10-membered mono-, bi- or spirocyclic ring wherein said ring, apart from the nitrogen atom, may optionally contain 0 to 4 additional heteroatoms selected from the group consisting of O, N and S and wherein said ring optionally is substituted by F, Cl, Br, CF_3, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_8)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, (C_0-C_8)-alkylene-aryl, oxo, CO(R46), CON(R47)(R48), OH, COO(R49), N(R50)CO(C_1-C_6)-alkyl, N(R51)(R52) or SO_2CH_3;

R46, R47, R48, R49, R50, R51 and R52 independently are H or (C_1-C_4)-alkyl;

o is 0, 1, 2, 3, 4, 5 or 6;

R45 is OH, $CH(aryl)_2$, a 3- to 12-membered mono- or bicyclic ring which optionally contains one or more heteroatoms selected from the group consisting of N, O and S wherein the 3- to 12-membered ring optionally is substituted by F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, oxo, O-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, S-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_3$-$C_8)$-cycloalkyl, O-$(C_3$-$C_8)$-cycloalkyl, $(C_3$-$C_8)$-cycloalkenyl, O-$(C_3$-$C_8)$-cycloalkenyl, $(C_2$-$C_6)$-alkynyl, $(C_0$-$C_8)$-alkylene-aryl, O-$(C_0$-$C_8)$-alkylene-aryl, S-aryl, N(R51)(R52), SO_2-CH_3 or COOH.

19. (withdrawn):The method of claim 18 wherein the antiobesity agent or appetite-regulating active ingredient is selected from the group consisting of leptin, modified leptin, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, the mono- and bis-demethylated active metabolites of sibutramine, orlistat, mazindol, diethylpropion and phenteramine.

20. (withdrawn): A method for the treatment or prevention of Type II diabetes in mammals comprising administering to said mammal a therapeutically effective amount of a mixture of one or more antidiabetics or hypoglycemic active ingredients and a compound, or a pharmaceutically acceptable salt thereof, of formula (I)



(I)

wherein

R is $(C_1$-$C_8)$-alkyl, $(C_0$-$C_8)$-alkylene-aryl, $(C_3$-$C_8)$-cycloalkyl, $(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, $(C_2$-$C_8)$-alkenyl, $(C_2$-$C_8)$-alkynyl, a 3- to 12-membered mono-, bi- or spirocyclic ring optionally containing one or more heteroatoms selected from the group consisting of N, O, and S, and wherein the 3- to 12-membered ring is optionally substituted by F, Cl, Br, NO_2, CF_3, OCF_3, CN, $(C_1$-$C_6)$-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-$(C_1$-$C_6)$-alkyl, S-$(C_1$-$C_6)$-alkyl, N(R15)CO$(C_1$-$C_6)$-alkyl or COO-$(C_1$-$C_6)$-alkyl;

R11, R12, R13, R14 and R15 independently are H or $(C_1$-$C_6)$-alkyl;

B is a bond or a linker comprising one or two radicals selected from the group consisting of $(C(R19)(R20))_i$, C(OR21)(R22), O, N(R23), S, SO, SO_2, and CO;

i is 1, 2 or 3;

R19, R20, R21, R22 and R23 independently are H, $(C_1$-$C_6)$-alkyl or aryl;

R1, R2, R3, and R4 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, S-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_3$-$C_8)$-cycloalkyl, O-$(C_3$-$C_8)$-cycloalkyl, $(C_3$-$C_8)$-cycloalkenyl, O-$(C_3$-$C_8)$-cycloalkenyl, $(C_2$-$C_6)$-alkynyl, $(C_0$-$C_8)$-alkylene-aryl, O-$(C_0$-$C_8)$-alkylene-aryl, S-aryl, N(R24)(R25), SO_2-CH_3, COOH, COO-$(C_1$-$C_6)$-alkyl, CON(R26)(R27), N(R28)CO(R29), N(R30) SO_2(R31) or CO(R32);

R24, R25, R26, R27, R28 and R30 independently are H or $(C_1$-$C_6)$-alkyl;

R29, R31,and R32 independently are H, $(C_1$-$C_6)$-alkyl or aryl;

W is $-(CH_2)_n$-, -CH=CH-, -CH=N- or –N=CH-;

n is 2, 3, 4 or 5;

R5, R6, R7 and R8 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-$(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, S-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_3$-$C_8)$-cycloalkyl, O-$(C_3$-$C_8)$-cycloalkyl, $(C_3$-$C_8)$-cycloalkenyl, O-$(C_3$-$C_8)$-cycloalkenyl, $(C_2$-$C_6)$-alkynyl, $(C_0$-$C_8)$-alkylene-aryl, O-$(C_0$-$C_8)$-alkylene-aryl, S-aryl, N(R33)(R34), SO_2-CH_3, COOH, COO-$(C_1$-$C_6)$-alkyl, CON(R35)(R36), N(R37)CO(R38), N(R39) SO_2(R40), CO(R41) or a 5- to 7-membered heterocycle having 1 to 4 heteroatoms selected from the group consisting of O, N and S;

R33 and R34 independently are H or (C_1-C_6)-alkyl, or
R33 and R34 form together with the nitrogen atom to which they are bonded a 5- or 6-membered ring wherein when R33 and R34 form together with the nitrogen to which they are bonded a 6-membered ring, one CH_2 group of the 6-membered ring optionally is O or S;

R35, R36, R37 and R39 independently are H or (C_1-C_6)-alkyl;

R38, R40 and R41 independently are H, (C_1-C_6)-alkyl or aryl;

A is a chain $-(C(R42)(R43))_m-$ wherein 0 to 2 members of the chain are optionally replaced by an element selected from the group consisting of O, S, N(R44), CO and SO_2;

m is 0, 1, 2, 3, 4 or 5;

R42, R43, R44 independently are H, (C_1-C_6)-alkyl or aryl;

R9 and R10 independently are H, (C_1-C_8)-alkyl, -$(CH_2)_o$-R45, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, aryloxy-(C_1-C_4)-alkyl, (C_3-C_8)-alkenyl, (C_3-C_8)-alkynyl, CO-(C_1-C_8)-alkyl, CO-$(CH_2)_o$R45, CO-(C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, CO-aryloxy-(C_1-C_4)-alkyl, CO-(C_2-C_8)-alkenyl, CO-(C_2-C_8)-alkynyl, or
R9 and R10 form together with the nitrogen atom to which they are bonded a 4- to 10-membered mono-, bi- or spirocyclic ring wherein said ring, apart from the nitrogen atom, may optionally contain 0 to 4 additional heteroatoms selected from the group consisting of O, N and S and wherein said ring optionally is substituted by F, Cl, Br, CF_3, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_8)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, (C_0-C_8)-alkylene-aryl, oxo, CO(R46), CON(R47)(R48), OH, COO(R49), N(R50)CO(C_1-C_6)-alkyl, N(R51)(R52) or SO_2CH_3;

R46, R47, R48, R49, R50, R51 and R52 independently are H or (C_1-C_4)-alkyl;

o is 0, 1, 2, 3, 4, 5 or 6;

R45 is OH, $CH(aryl)_2$, a 3- to 12-membered mono- or bicyclic ring which optionally contains one or more heteroatoms selected from the group consisting of N, O and S wherein the 3- to 12-membered ring optionally is substituted by F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, oxo, O-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, S-$(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_3$-$C_8)$-cycloalkyl, O-$(C_3$-$C_8)$-cycloalkyl, $(C_3$-$C_8)$-cycloalkenyl, O-$(C_3$-$C_8)$-cycloalkenyl, $(C_2$-$C_6)$-alkynyl, $(C_0$-$C_8)$-alkylene-aryl, O-$(C_0$-$C_8)$-alkylene-aryl, S-aryl, N(R51)(R52), SO_2-CH_3 or COOH.

21. (withdrawn): The method of claim 20 wherein said antidiabetic or hypoglycemic active ingredient is selected from the group consisting of insulin, a sulfonylurea, a biguanide, a meglitinide, a thiazolidinedione, an oxadiazolidinedione and an α-glucosidase inhibitor.

22. (currently amended): A pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of formula (I)



(I)

wherein

R is $(C_1$-$C_8)$-alkyl, $(C_0$-$C_8)$-alkylene-aryl, $(C_3$-$C_8)$-cycloalkyl, $(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, $(C_2$-$C_8)$-alkenyl, $(C_2$-$C_8)$-alkynyl, a 3- to 12-membered mono-, bi- or spirocyclic ring optionally containing one ~~or more~~ heteroatoms selected from the group consisting of N, O, and S, and wherein the 3- to 12-membered ring is optionally substituted by F, Cl, Br, NO_2, CF_3, OCF_3, CN, $(C_1$-$C_6)$-alkyl, aryl, CON(R11)(R12), N(R13)(R14), OH, O-$(C_1$-$C_6)$-alkyl, S-$(C_1$-$C_6)$-alkyl, or N(R15)CO$(C_1$-$C_6)$-alkyl ~~or COO-$(C_1$-$C_6)$-alkyl~~;

R11, R12, R13, R14 and R15 independently are H or $(C_1$-$C_6)$-alkyl;

B is a bond or a linker ~~comprising~~ of one or two radicals selected from the group consisting of $(C(R19)(R20))_i$, C(OR21)(R22), O, N(R23), S, SO, SO_2, and CO;

i is 1, 2 or 3;

R19, R20, R21, R22 and R23 independently are H, (C_1-C_6)-alkyl or aryl;

R1, R2, R3, and R4 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)-alkyl, O-(C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, S-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_3-C_8)-cycloalkyl, O-(C_3-C_8)-cycloalkyl, (C_3-C_8)-cycloalkenyl, O-(C_3-C_8)-cycloalkenyl, (C_2-C_6)-alkynyl, (C_0-C_8)-alkylene-aryl, O-(C_0-C_8)-alkylene-aryl, S-aryl, N(R24)(R25), SO_2-CH_3, ~~COOH, COO-(C_1-C_6)-alkyl,~~ CON(R26)(R27), N(R28)CO(R29), N(R30) SO_2(R31) or CO(R32);

R24, R25, R26, R27, R28 and R30 independently are H or (C_1-C_6)-alkyl;

R29, R31,and R32 independently are H, (C_1-C_6)-alkyl or aryl;

W is $-(CH_2)_n-$, -CH=CH-, -CH=N- or –N=CH-;

n is 2, 3, 4 or 5;

R5, R6, R7 and R8 independently are H, F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)-alkyl, O-(C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, S-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_3-C_8)-cycloalkyl, O-(C_3-C_8)-cycloalkyl, (C_3-C_8)-cycloalkenyl, O-(C_3-C_8)-cycloalkenyl, (C_2-C_6)-alkynyl, (C_0-C_8)-alkylene-aryl, O-(C_0-C_8)-alkylene-aryl, S-aryl, N(R33)(R34), SO_2-CH_3, ~~COOH, COO-(C_1-C_6)-alkyl,~~ CON(R35)(R36), N(R37)CO(R38), N(R39) SO_2(R40), CO(R41) or a 5- to 7-membered heterocycle having 1 ~~to 4~~ heteroatoms selected from the group consisting of O, N and S;

R33 and R34 independently are H or (C_1-C_6)-alkyl, or
R33 and R34 form together with the nitrogen atom to which they are bonded a 5- or 6-membered ring wherein when R33 and R34 form together with the nitrogen to which they are bonded a 6-membered ring, one CH_2 group of the 6-membered ring optionally is O or S;

R35, R36, R37 and R39 independently are H or (C_1-C_6)-alkyl;

R38, R40 and R41 independently are H, (C_1-C_6)-alkyl or aryl;

A is a chain $-(C(R42)(R43))_m-$ wherein 0 to 2 members of the chain are optionally replaced by an element selected from the group consisting of O, S, N(R44), CO and SO_2;

m is 0, 1, 2, 3, 4 or 5;

R42, R43, R44 independently are H, (C_1-C_6)-alkyl or aryl;

R9 and R10 independently are H, (C_1-C_8)-alkyl, $-(CH_2)_o$-R45, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, aryloxy-(C_1-C_4)-alkyl, (C_3-C_8)-alkenyl, (C_3-C_8)-alkynyl, CO-(C_1-C_8)-alkyl, CO-$(CH_2)_o$R45, CO-(C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, CO-aryloxy-(C_1-C_4)-alkyl, CO-(C_2-C_8)-alkenyl, CO-(C_2-C_8)-alkynyl, or
R9 and R10 form together with the nitrogen atom to which they are bonded a 4- to 10-membered mono-, bi- or spirocyclic ring wherein said ring, apart from the nitrogen atom, may optionally contain 0 to 4 additional heteroatoms selected from the group consisting of O, N and S and wherein said ring optionally is substituted by F, Cl, Br, CF_3, NO_2, CN, (C_1-C_6)-alkyl, O-(C_1-C_8)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, (C_0-C_8)-alkylene-aryl, oxo, CO(R46), CON(R47)(R48), OH, ~~COO(R49),~~ N(R50)CO(C_1-C_6)-alkyl, N(R51)(R52) or SO_2CH_3;

R46, R47, R48, ~~R49,~~ R50, R51 and R52 independently are H or (C_1-C_4)-alkyl;

o is 0, 1, 2, 3, 4, 5 or 6;

R45 is OH, $CH(aryl)_2$, a 3- to 12-membered mono- or bicyclic ring which optionally contains one or more heteroatoms selected from the group consisting of N, O and S wherein the 3- to 12-membered ring optionally is substituted by F, Cl, Br, I, OH, CF_3, NO_2, CN, OCF_3, oxo, O-(C_1-C_6)-alkyl, (C_1-C_4)-alkoxy-(C_1-C_4)-alkyl, S-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_3-C_8)-cycloalkyl, O-(C_3-C_8)-cycloalkyl, (C_3-C_8)-cycloalkenyl, O-

(C_3-C_8)-cycloalkenyl, (C_2-C_6)-alkynyl, (C_0-C_8)-alkylene-aryl, O-(C_0-C_8)-alkylene-aryl, S-aryl, N(R51)(R52), SO_2-CH_3 or COOH.

23. (original): A pharmaceutical composition according to claim 22 further comprising a therapeutically effective amount of one or more compounds selected from the group consisting of an antiobesity agent, an appetite-regulating active ingredient, an antidiabetic and a hypoglycemic active ingredient.

24. (original): A pharmaceutical composition according to claim 23 wherein said antiobesity agent or appetite-regulating active ingredient is selected from the group consisting of of leptin, modified leptin, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, the mono- and bis-demethylated active metabolites of sibutramine, orlistat, mazindol, diethylpropion and phenteramine.

25. (original): A pharmaceutical composition according to claim 23 wherein said antidiabetic or hypoglycemic active ingredient is selected from the group consisting of insulin, a sulfonylurea, a biguanide, a meglitinide, a thiazolidinedione, an oxadiazolidinedione and an α-glucosidase inhibitor.

26. (new): A compound of formula (I)



(I)

R is (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl, or a 5- to 6-membered mono- or bicyclic ring optionally containing one or two heteroatoms selected from the group consisting of N, O, and S, wherein the 5- to 6-membered ring is optionally substituted by F, Cl, Br, NO_2, CF_3, OCF_3, CN, (C_1-C_6)-alkyl or O-(C_1-C_6)-alkyl;

B is a bond, O, S, $COOCH_2$, N(R23) or CH_2;

R23 is H or (C_1-C_6)-alkyl;

R1, R2, R3, and R4 independently are H, F, Cl, Br, CF_3, O-(C_1-C_6)-alkyl or (C_1-C_6)-alkyl;

W is –CH=CH- or –N=CH-;

R5, R6, R7 and R8 independently are H, F, Cl, Br, OH, CF_3, NO_2, CN, OCF_3 or O-(C_1-C_6)-alkyl;

A is a chain –(C(R42)(R43))$_m$- wherein 1 member of the chain is optionally replaced by an element selected from the group consisting of O and N(R44);

m is 0, 1, 2, 3, 4 or 5;

R42, R43, and R44 independently are H, (C_1-C_6)-alkyl or aryl;

R9 and R10 independently are H, (C_1-C_8)-alkyl, -(CH_2)$_o$-R45 or CO-(C_1-C_8)-alkyl; or
R9 and R10 form together with the nitrogen atom to which they are bonded a 4- to 10-membered mono-, bi- or spirocyclic ring wherein said ring, apart from the nitrogen atom, may optionally contain 0 to 2 additional heteroatoms selected from the group consisting of O, N and S, and wherein said ring optionally is substituted by F, (C_1-C_6)-alkyl, O-(C_1-C_8)-alkyl, oxo, CO(R46), CON(R47)(R48), OH, N(R50)CO(C_1-C_6)-alkyl or N(R51)(R52);

R46, R47, R48, R50, R51, and R52 independently are H or (C_1-C_4)-alkyl;

o is 0, 1, 2, 3, 4, 5 or 6;

R45 is OH, a 5- to 10-membered mono- or bicyclic ring which optionally contains one or two heteroatoms selected from the group consisting of N, O and S, wherein the 5- to 10-membered ring optionally is substituted by F, Cl, Br, OH, CF_3, oxo, O-(C_1-C_6)-alkyl, (C_1-C_6)-alkyl, (C_0-C_2)-alkylene-aryl, O-(C_0-C_2)-alkylene-aryl or N(R51)(R52).

27. (new): The compound according to claim 26 wherein W is –CH=CH-.

28. (new): The compound according to claim 26 wherein m is 3 and R42, R43 and R44 are H.

29. (new): The compound according to claim 26 wherein R5, R6, R7 and R8 are H.

30. (new): The compound according to claim 26 wherein A and B are each disposed in the para position relative to the central W-containing heterocycle.